Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ:VNDA
Vanda (VNDA) Stock Price & Analysis
413 Followers
VNDA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.30 - $6.75
Previous Close$5.58
Volume1.32M
Average Volume (3M)2.63M
Market Cap
$324.75M
Enterprise Value-$56.51M
Total Cash (Recent Filing)$388.26M
Total Debt (Recent Filing)$7.01M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Jul 31, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding58,198,273
10 Day Avg. Volume1,518,166
30 Day Avg. Volume2,634,452
Standard Deviation0.13
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.84
Price to Sales (P/S)7.87
Price to Cash Flow (P/CF)-23.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.29
Enterprise Value/Gross Profit-0.32
Enterprise Value/Ebitda-16.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Vanda News
Ownership Overview
29.31% Insiders
22.63% Mutual Funds
27.53% Other Institutional Investors
20.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VNDA FAQ
What was Vanda Pharmaceuticals Inc.’s price range in the past 12 months?
Vanda Pharmaceuticals Inc. lowest stock price was $3.29 and its highest was $6.75 in the past 12 months.
What is Vanda Pharmaceuticals Inc.’s market cap?
Currently, no data Available
When is Vanda Pharmaceuticals Inc.’s upcoming earnings report date?
Vanda Pharmaceuticals Inc.’s upcoming earnings report date is Jul 31, 2024 which is in 28 days.
How were Vanda Pharmaceuticals Inc.’s earnings last quarter?
Vanda Pharmaceuticals Inc. released its earnings results on May 08, 2024. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of $0.05 by -$0.12.
Is Vanda Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Vanda Pharmaceuticals Inc.’s price is currently Overvalued.
Does Vanda Pharmaceuticals Inc. pay dividends?
Vanda Pharmaceuticals Inc. does not currently pay dividends.
What is Vanda Pharmaceuticals Inc.’s EPS estimate?
Vanda Pharmaceuticals Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vanda Pharmaceuticals Inc. have?
Vanda Pharmaceuticals Inc. has 58,198,273 shares outstanding.
What happened to Vanda Pharmaceuticals Inc.’s price movement after its last earnings report?
Vanda Pharmaceuticals Inc. reported an EPS of -$0.07 in its last earnings report, missing expectations of $0.05. Following the earnings report the stock price went down -6.53%.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals Inc.?
Among the largest hedge funds holding Vanda Pharmaceuticals Inc.’s share is Graham Capital Management, L.P.. It holds Vanda Pharmaceuticals Inc.’s shares valued at 111K.
---
Vanda Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
VNDA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.2%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.32%
12-Months-Change
Fundamentals
Return on Equity
-0.91%
Trailing 12-Months
Asset Growth
1.26%
Trailing 12-Months
Company Description
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
---
VNDA Earnings Call
Q1 2024
0:00 / 0:00
---
Technical Analysis
---